Summary
This Phase 3 clinical trial reported extended follow-up data from IMvigor211, comparing atezolizumab immunotherapy with standard chemotherapy in patients with advanced urothelial carcinoma previously treated with platinum-based regimens. As a cancer immunotherapy trial published in European Urology in 2021, the study provides long-term survival and safety evidence relevant to treatment decisions in this indication, though detailed outcomes cannot be confirmed without access to the full text.
UK applicability
Findings from this international oncology trial may inform National Health Service treatment protocols and NICE guidance for urothelial carcinoma management in the United Kingdom, where atezolizumab and similar immunotherapies are evaluated for reimbursement and clinical use.
Key measures
Overall survival, safety profile, adverse events
Outcomes reported
This study reported long-term overall survival and safety outcomes comparing atezolizumab (an immunotherapy agent) with chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma. The trial assessed efficacy and tolerability in this patient population as a follow-up to earlier IMvigor211 phase 3 trial results.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.